Dienstag, 24. Dezember 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Rekrutierend

NCT-Nummer:
NCT05556096

Studienbeginn:
November 2022

Letztes Update:
07.08.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Myasthenia Gravis, Muscle Weakness

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Alexion Pharmaceuticals, Inc.

Collaborator:
-

Kontakt

Alexion Pharmaceuticals, Inc. (Sponsor)
Kontakt:
Phone: 1-855-752-2356
E-Mail: clinicaltrials@alexion.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 163)

Research Site
40225 Düsseldorf
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
72076 Tübingen
(Baden-Württemberg)
GermanyZurückgezogen» Google-Maps
Research Site
90095-1624 Los Angeles
United StatesRekrutierend» Google-Maps
Research Site
92270 Rancho Mirage
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
29406 North Charleston
United StatesRekrutierend» Google-Maps
Research Site
1015 Buenos Aires
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Research Site
AR-CP 1221 Buenos Aires
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Research Site
C1192AAW Caba
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Research Site
C1428AQK Capital Federal
ArgentinaZurückgezogen» Google-Maps
Research Site
S2000BZL Rosario
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Research Site
14784-400 Barretos
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
89202-190 Joinville
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
90110-000 Porto Alegre
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
14051-140 Ribeirão Preto
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
41253-190 Salvador
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
15090-000 Sao Jose Do Rio Preto
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
05403-000 Sao Paulo
BrazilAktiv, nicht rekrutierend» Google-Maps
Research Site
S10 2JF Sheffield
United KingdomNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the

treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine

receptor (AChR).

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Diagnosis of MG with generalized muscle weakness meeting the clinical criteria

defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV

- Positive serological test for autoantibodies against AChR

Exclusion Criteria:

- History of thymectomy, or any other thymic surgery within 12 months prior to

Screening

- Untreated thymic malignancy, carcinoma, or thymoma

- History of Neisseria meningitidis infection

- Pregnancy, breastfeeding, or intention to conceive during the course of the study

Studien-Rationale

Primary outcome:

1. Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26 (Time Frame - Baseline, Week 26)



Secondary outcome:

1. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26 (Time Frame - Baseline, Week 26)

2. Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26 (Time Frame - Baseline up to Week 26):
Response is defined as reduction of the MG-ADL total score by >= 3 points from baseline at Week 26.

3. Percentage of Responders based on Reduction of the QMG Total Score at Week 26 (Time Frame - Baseline up to Week 26):
Response is defined as reduction of the QMG total score by >= 5 points from baseline at Week 26

4. Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26 (Time Frame - Baseline, Week 26)

Studien-Arme

  • Experimental: ALXN1720
    Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks.
  • Placebo Comparator: Placebo
    Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.

Geprüfte Regime

  • ALXN1720:
    Combination product consisting of syringe prefilled with ALXN1720.
  • Placebo:
    Combination product consisting of syringe prefilled with placebo.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.